- Home
- CWK vs LIVN Comparison
CWK vs LIVN Comparison
Compare CWK & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | LIVN |
|---|---|---|
| Founded | 1784 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2018 | 1993 |
Fundamental Metrics
Financial Performance| Metric | CWK | LIVN |
|---|---|---|
| Price | $17.03 | $63.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $18.07 | ★ $67.38 |
| AVG Volume (30 Days) | ★ 1.4M | 549.7K |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.30 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,003,900,000.00 | $1,348,962,000.00 |
| Revenue This Year | $8.47 | $12.25 |
| Revenue Next Year | $2.02 | $6.68 |
| P/E Ratio | $17.47 | ★ N/A |
| Revenue Growth | 6.77 | ★ 8.63 |
| 52 Week Low | $7.64 | $32.48 |
| 52 Week High | $17.33 | $65.57 |
Technical Indicators
Market Signals| Indicator | CWK | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 53.72 |
| Support Level | $16.33 | $60.79 |
| Resistance Level | $17.21 | $64.10 |
| Average True Range (ATR) | 0.60 | 1.61 |
| MACD | 0.02 | -0.20 |
| Stochastic Oscillator | 81.25 | 54.71 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.